FutureFuel: A Two-Year-High Run Rate, a $4.9 Million Hole, and a 42% Slide
Biofuel utilization hit 83% and revenue tripled — yet a gross loss, $21M of cash, and a frozen buyback sent the stock down 42% in three sessions, as management pivots to European reshoring and glycerin.
FF · Earnings Call · 2026-11-10
The Crash Into the Print
Something broke in FutureFuel's stock right before this call. The tape tells the story bluntly: shares fell 42% in three sessions on the eve of the report, dragging the whole move since mid-August to a -46.7% return and a drawdown from the $5.85 peak that is, for practical purposes, the entire decline. That is not a company quietly missing a number. That is a repricing — and the transcript explains why the market reached for the red pen.Two Businesses, One Loss
The top line looks spectacular and misleading in equal measure. “Total revenue increased 361.3% to $104.7 million during the third quarter, up from $22.7 million last year.” — Rose Sparks, Chief Financial Officer · 2026-11-10 Yet the same quarter produced a $5.4 million gross loss, a $8.4 million net loss, and a $4.9 million adjusted EBITDA loss. Two operating narratives ran side by side. In biofuels, execution was genuinely excellent: capacity utilization reached 83%, the highest in more than two years, and management says it is effectively booked through the fourth quarter. But elevated feedstock — soybean oil at all-time highs — plus derivative losses of $8.7 million net dragged the segment to a $9.8 million gross loss. In chemicals, dedicated-unit turnarounds for two customers cut volumes 27% and pushed customer A to pause its order cadence while it rebalanced inventory; segment utilization fell to 32% from 55%. CEO Roeland Polet calls this an anomaly. “Q3 was an atypical quarter... we feel is coming back a lot more to a more typical operating rate of our plant.” — Roeland Polet, Chairman and Chief Executive Officer · 2026-11-10 The historical shape argues for caution. Gross profit swung from +$15 million in Q2 2026 to a $5.4 million loss in Q3, and the prior four quarters were all negative. On Net income and Free cash flow, this is a spread business whose quarterly results are hostage to commodity timing. "Atypical" is doing a lot of work in that sentence.The New Story: Reshoring and Glycerin
The one genuinely fresh thread is European reshoring. A large European chemicals producer is moving U.S.-bound production onto the Batesville site, with initial batch output in Q1 2027 and full rates by mid-2027. This is a new entry in the company's vocabulary — reshoring opportunities climbs into the current-quarter narrative for the first time — and it rhymes with the market's broader U.S. manufacturing footprint theme, where cheap American natural gas is pulling European chemistry across the Atlantic.The second lever is refined glycerin. FutureFuel's biodiesel waste stream can be upgraded and sold for roughly three times the per-gallon value of crude glycerin, for under $1 million of capex, yielding a $5–10 million opportunity beginning in 2027. What makes this delicious is the echo: a decade ago, then-executive Paul Flynn described “having the optionality of selling in the refined or the crude form, depending on market conditions, it's a nice optionality card to have.” — Paul Flynn, CEO · 2015-03-13 The card is finally being cashed.It probably is an even bigger opportunity than the reshoring activity from China and India. And we anticipate that this won't be the last customer that we see looking to reshore.